by Hansraj Agrawal | Sep 28, 2024 | Share Market
Last Updated : Sep 28 2024 | 3:04 PM IST
Lupin announced that its Pithampur facility in Madhya Pradesh, which includes the unit-1 API and finished product manufacturing site, was inspected by the U.S. Food and Drug Administration (USFDA) from 16 September to 27 September 2024.
The inspection concluded with 3 observations on both the API and Finished Product sides. The pharmaceutical major is addressing these observations comprehensively and will respond to the USFDA within the stipulated timeframe.
Click here to connect with us on WhatsApp
Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The companys consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter.
Shares of Lupin gained 1.56% to end at Rs 2,221.50 on Friday, 27 September 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Sep 28 2024 | 2:54 PM IST
Source link
by Hansraj Agrawal | Sep 28, 2024 | Share Market
Last Updated : Sep 28 2024 | 3:50 PM IST
Zydus Lifesciences announced that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg.
The Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
The drug will be manufactured at the groups formulation manufacturing facility in Moraiya, Ahmedabad.
Click here to connect with us on WhatsApp
According to IQVIA MAT July 2024, Enzalutamide capsules, 40 mg, generated annual sales of $869.4 million in the United States.
With this approval, the group now holds a total of 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs) since the filing process began in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The pharma companys consolidated net profit surged 30.64% to Rs 1,419.9 crore in Q1 FY25 as compared to Rs 1,086.9 crore posted in Q1 FY24. Revenue from operations jumped 20.77% year on year (YoY) to Rs 6,207.5 crore in the quarter ended 30 June 2024.
Shares of Zydus Lifesciences rose 0.59% to end at Rs 1,074.60 on Friday, 27 September 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Sep 28 2024 | 2:42 PM IST
Source link
by Hansraj Agrawal | Sep 28, 2024 | Share Market
Last Updated : Sep 28 2024 | 2:31 PM IST
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg (USRLD: Xtandi Capsules, 40 mg).
Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer. Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad.
Enzalutamide capsules, 40 mg had annual sales of USD 869.4 mn in the United States (IQVIA MAT July 2024).
Click here to connect with us on WhatsApp
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Sep 28 2024 | 2:21 PM IST
Source link
by Hansraj Agrawal | Sep 28, 2024 | Share Market
Last Updated : Sep 28 2024 | 2:31 PM IST
With effect from 24 December 2024
Bandhan Bank announced that Manoj Kumar Mauni, Chief
Technology Officer of the Bank, has tendered his resignation from the services of the Bank. He would continue with the services
in terms of the policies of the Bank, and his last working day with the Bank would be 24 December 2024.
Powered by Capital Market – Live News
Click here to connect with us on WhatsApp
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Sep 28 2024 | 2:13 PM IST
Source link
by Hansraj Agrawal | Sep 28, 2024 | Share Market
Last Updated : Sep 28 2024 | 1:16 PM IST
Alembic Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had issued an establishment inspection report (EIR) for its oral solid formulation facility (F-1) located in Panelav, Gujarat.
Earlier, on 26 July 2024, the pharmaceutical company informed that it had successfully completed the USFDA inspection of its Oral Solid Formulation Facility (F-I) in Panelav.
This scheduled GMP inspection was completed without any form 483 observations. The inspection had been conducted from 17 July 2024 to 26 July 2024.
Click here to connect with us on WhatsApp
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The pharmaceutical companys consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.
Shares of Alembic Pharma shed 0.27% to settle at Rs 1,192.65 on Friday 27 September 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Sep 28 2024 | 1:02 PM IST
Source link
by Hansraj Agrawal | Sep 28, 2024 | Share Market
Last Updated : Sep 28 2024 | 1:16 PM IST
Alembic Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had issued an establishment inspection report (EIR) for its oral solid formulation facility (F-1) located in Panelav, Gujarat.
Earlier, on 26 July 2024, the pharmaceutical company informed that it had successfully completed the USFDA inspection of its Oral Solid Formulation Facility (F-I) in Panelav.
This scheduled GMP inspection was completed without any form 483 observations. The inspection had been conducted from 17 July 2024 to 26 July 2024.
Click here to connect with us on WhatsApp
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The pharmaceutical companys consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.
Shares of Alembic Pharma shed 0.27% to settle at Rs 1,192.65 on Friday 27 September 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Sep 28 2024 | 1:02 PM IST
Source link
